6533b871fe1ef96bd12d255a

RESEARCH PRODUCT

Efficacy and safety of clarithromycin as treatment for Mediterranean spotted fever in children: a randomized controlled trial

Antonio CascioDomenico Di RosaClaudia ColombaL SalsaLucio Di MartinoLucina Titone

subject

Microbiology (medical)Malemedicine.medical_specialtyBoutonneuse FeverGastroenterologylaw.inventionRandomized controlled trialOral administrationlawClarithromycinInternal medicineClarithromycinmedicineHumansChildAntibacterial agentclarithromycin Mediterranean spotted feverbusiness.industryChloramphenicolmedicine.diseaseSpotted feverSurgeryAnti-Bacterial AgentsBoutonneuse feverInfectious DiseasesRickettsiosisChloramphenicolChild PreschoolFemalebusinessmedicine.drug

description

Fifty-one children with Mediterranean spotted fever (MSF) were randomized to receive either clarithromycin, 15 mg/kg/ day orally in 2 divided doses, or chloramphenicol, 50 mg/ kg/day orally in 4 divided doses, for 7 days. Mean time to defervescence was 36.7 h in the clarithromycin group and 47.1 h in the chloramphenicol group (P = .047). Clarithromycin could be an acceptable therapeutic alternative to chloramphenicol and to tetracyclines for children aged <8 years with MSF.

yearjournalcountryeditionlanguage
2001-08-01
http://hdl.handle.net/10447/63391